Timothy syndrome (TS) is a genetic disorder causing excessive cellular Ca 2ϩ entry resulting from defective voltage-dependent inactivation of the predominant myocardial L-type Ca 2ϩ channel (Ca V 1.2) current (I Ca ). TS patients die on average at 2.5 years of age as a result of malignant cardiac arrhythmias. TS is a "model" disease whereby a concise biophysical defect in I Ca activates a cellular signaling cascade that is required for the cardiac disease phenotypes. Our studies showed that loss of voltage-dependent inactivation leads to cellular arrhythmias by recruiting activity of the calmodulindependent protein kinase II (CaMKII). The role of CaMKII was not anticipated by previous computer models that relied on data obtained from nonexcitable, heterologous cells. Our studies show that the TS voltage-dependent inactivation defect activated CaMKII and that CaMKII was the feed-forward signal required for the proarrhythmic cellular phenotypes in TS. These findings have potentially broad implications for other pathological phenotypes in TS such as autism and for other genetic diseases affecting Ca 2ϩ channels such as migraine headache, myasthenia, ataxia, and malignant hyperthermia. Diseases associated with excitable cells in which ion channels frequently constitute a final common pathway require careful consideration of the connections between ion channel gating and signaling cascades to more comprehensively understand the underlying mechanisms. See p 2225.
Association Between Intraoperative and Early Postoperative Glucose Levels and Adverse Outcomes After Complex Congenital Heart Surgery
Hyperglycemia occurs commonly and has been associated with increased morbidity and mortality in critically ill adults, including those undergoing cardiac surgery. The use of insulin to achieve strict glycemic control may improve outcomes in these patients. The aim of this cohort study was to determine whether adjusted associations exist between intraoperative or early postoperative metrics of glucose control and longer hospitalization or adverse outcomes after complex congenital heart surgery. After multivariate analysis, we found that none of the intraoperative glucose variables were associated with duration of hospitalization, but a minimum glucose Յ75 mg/dL was associated with greater adjusted odds of reaching the composite morbidity-mortality end point. Postoperatively, greater duration of glucose levels Ͼ126 mg/dL during the first 72 hours after surgery was associated with longer hospital stay. Patients with average glucose levels Ͻ110 or Ͼ143 mg/dL, higher peak glucose levels, and lower minimum glucose levels all have greater adjusted odds for reaching the composite morbidity-mortality end point. Taken together, the associations we found between the various metrics of glucose control and adverse outcomes suggest that the ideal postoperative glucose range after complex congenital heart surgery is 110 to 126 mg/dL, which is higher than the target range that some experts recommend for critically ill adults. The associations we identified between various metrics of glucose control and the outcome measures are insufficient to prove causality. Randomized controlled trials are needed to determine whether achieving strict glycemic control with an insulin infusion is beneficial for children recovering from congenital heart surgery. See p 2235.
C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men
High-sensitivity C-reactive protein and family history are independently associated with cardiovascular events and have been incorporated into risk prediction models for women (the Reynolds Risk Score for women); however, no cardiovascular risk prediction algorithm incorporating these variables exists for men. We assessed the incremental benefit of adding high-sensitivity C-reactive protein and parental history of premature atherosclerosis to the traditional factors of age, blood pressure, smoking, and total and high-density lipoprotein cholesterol in a prospective cohort of 10 724 initially healthy nondiabetic men. Compared with the traditional model, the Reynolds Risk Score had better global fit, a superior (lower) Bayes information criterion, and a larger C-index. More importantly, use of the Reynolds Risk Score for men reclassified 18% of the study population (and 20% of those at intermediate risk) into higher-or lower-risk categories, with markedly improved accuracy among those reclassified. Thus, as previously shown in women, a prediction model in men that incorporates high-sensitivity C-reactive protein and parental history significantly improves global cardiovascular risk prediction. User-friendly calculators for the Reynolds Risk Scores for men and women can be freely accessed at http://www. reynoldsriskscore.org. Beyond computation of 10-year risk, this World Wide Web site also includes patient-centered data on lifetime risk and provides estimates of risk reductions that can be anticipated with the implementation of lifestyle change, smoking cessation, blood pressure control, and lipid reduction. Use of the Reynolds Risk Scores could allow more accurate targeting of lipid-lowering therapy to those with the most appropriate levels of risk, thus increasing its net benefit and decreasing toxicity. See p 2243.
Relations of Biomarkers Representing Distinct Biological Pathways to Left Ventricular Geometry
Several biological processes have been individually implicated in left ventricular (LV) remodeling, but the relative contributions of these pathways are unclear. Such knowledge would be useful because LV remodeling precedes and predicts cardiovascular morbidity and mortality, and biological insights may aid risk stratification, elucidate therapeutic targets, or both. We used a multimarker strategy, which permitted a comparison of several biomarkers in relation to their contributions to LV remodeling while limiting multiple testing, to relate 6 biomarkers representing inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neuroendocrine activation (B-type natriuretic peptide), and the reninangiotensin-aldosterone system (aldosterone to renin ratio) to the 4 mutually exclusive patterns of LV geometry (ie, concentric remodeling, eccentric hypertrophy, concentric hypertrophy, and normal geometry). We performed this analysis in a large cohort of freeliving individuals without prevalent cardiovascular disease. In ageand sex-adjusted models, we observed that all biomarkers were strongly and positively related to altered LV geometry, specifically to eccentric and concentric hypertrophy. In multivariable models, aldosterone to renin ratio emerged as the major correlate of LV geometry, with strong positive associations with both eccentric and concentric hypertrophy. Our observations are consistent with a fundamental role for the renin-angiotensin-aldosterone system in 
Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
Hypertension remains the greatest population-attributable risk for developing heart failure. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) of 42 418 high-risk hypertensive patients, 1367 developed heart failure during follow-up. Of 910 with an estimate of left ventricular ejection fraction, 44% and 56% had preserved (ejection fraction Ն50%) and reduced ejection fraction, respectively. Mortality risk after heart failure onset was greatly increased in both the preserved and reduced ejection fraction groups compared with those who did not manifest heart failure, and heart failure patients with preserved ejection fraction had a lower case fatality rate than those with reduced ejection fraction. Compared with amlodipine and doxazosin, chlorthalidone reduced the incidence of heart failure with reduced and preserved ejection fraction; compared with lisinopril, chlorthalidone reduced the incidence of heart failure with preserved ejection fraction. See p 2259.
Novel Cardiac Apoptotic Pathway: The Dephosphorylation of Apoptosis Repressor With Caspase Recruitment Domain by Calcineurin
Heart failure is a leading cause of mortality worldwide. The ␤-adrenergic receptor system is broadly involved in growth control and apoptosis. Many clinical trials have indicated that ␤-adrenergic receptor blockers significantly improve survival rates in patients with heart failure by decreasing cardiac remodeling. The ␤-adrenergic receptor agonist isoproterenol promotes cardiac dysfunction resulting from cardiac remodeling, including apoptosis. Aldosterone has recently attracted considerable attention for its involvement in the pathophysiology of heart failure. A study performed in patients with cardiac failure shows a significant reduction in morbidity and mortality with the use of the aldosterone antagonists spironolactone or eplerenone in the therapy. Hitherto, the molecular mechanisms by which isoproterenol or aldosterone induce cardiac apoptosis have not been fully elucidated. Apoptosis repressor with caspase recruitment domain (ARC) is a cardiac-abundant antiapoptotic protein. Its antiapoptotic function is dependent on threonine-149 phosphorylation by protein kinase CK2. The present study reveals that isoproterenol and aldosterone are able to induce ARC dephosphorylation through calcineurin, thereby leading to the inability of ARC to antagonize apoptosis. These data suggest that the dephosphorylation of ARC by calcineurin may constitute an apoptotic pathway in the heart. The present study can provide information for exploring the beneficial effects of this cardiac-abundant protein on apoptosisrelated cardiac diseases such as heart failure. See p 2268.
Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus: Results From the Massachusetts Data Analysis Center Registry
Patients with diabetes mellitus are at high risk for restenosis, myocardial infarction, and cardiac mortality after coronary stenting. In randomized comparisons, drug-eluting stents (DES) have reduced restenosis relative to bare-metal stents (BMS); however, data on the long-term outcomes of DES in diabetes mellitus are conflicting. This population-based study prospectively collected clinical and procedural data on all diabetic patients who underwent percutaneous coronary intervention with stents from April 1, 2003 , through September 30, 2004 , at all nonfederal hospitals in Massachusetts. The aim of the study was to evaluate the long-term safety of DES versus BMS specifically in patients with diabetes mellitus from a contemporary US population. Rates of mortality, myocardial infarction, and repeat revascularization procedures were ascertained over the 3 years after stent placement. Propensity-score-matched analysis was performed to compare DES-and BMS-treated patients because the choice of stent was not randomly assigned. Diabetes mellitus was present in 5051 patients (29% of the overall population) treated with DES or BMS during the study. Sixty-six percent of patients with diabetes mellitus received DES compared with 34% who received BMS. In the 1:1-matched DES versus BMS patients, the riskadjusted mortality, myocardial infarction, and target vessel revascularization rates at 3 years were lower in the diabetic patients treated with DES compared with BMS. The results of this large populationbased study suggest that DES are safe and effective in patients with diabetes mellitus undergoing percutaneous coronary intervention with stenting in long-term follow-up. See p 2277.
